Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2011

View Archived Issues

CalciMedica begins phase I trial of CM-2489 for psoriasis

FDA grants orphan drug status to MGN-4893 in polycythemia vera

Phase I/II trial of panobinostat/bicalutamide combination in prostate cancer advances

IST5-002 shows promise in models of prostate cancer

MedTrust Online and Avantra partner to validate cancer biomarker assays

Brusatol suppresses development of resistance to chemotherapeutic agents in vivo

Gelsolin is a putative biomarker in subarachnoid hemorrhage

Fractalkine is a potential target for drugs for Parkinson's disease

TB Alliance presents agents for tuberculosis and protozoal infections

Kancera acquires iNovacia

Omeros expands exclusive PDE7 inhibitor license from Daiichi Sankyo

Infinity Pharma begins phase II portion of IPI-926 trial in pancreatic cancer

IRM discloses new GPR119 receptor modulators

Regeneron submits BLA for VEGF Trap-Eye for wet AMD

Merck & Co. claims new activators of glycoprotein hormone FSH receptor

Angiochem receives NBTS innovation award for development of new brain cancer treatments

Kyowa Hakko Kirin to acquire ProStrakan

Encouraging phase IIa data reported on Cx-601 for perianal fistulas in patients with Crohn's disease

GSK presents novel GlyT1 inhibitors

AstraZeneca and Pulmagen present dual-acting agents for respiratory disorders

Gilead Sciences to acquire Calistoga Pharmaceuticals

Sanofi Pasteur and International Vaccine Institute join forces against dengue fever

Chugai's anticancer agent Xeloda approved for additional indication in Japan

Theratechnologies to launch new clinical program for tesamorelin in COPD-associated muscle wasting

Forest Labs enters into definitive merger agreement to acquire Clinical Data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...